Millennium Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Millennium Management’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$2.01M	–	7334
2022 Q4	$2.01M	Sell	200,000 -5,190	-3%	-$52K	﹤0.01%	3560
2022 Q3	$2.03M	Hold	205,190	–	–	﹤0.01%	3723
2022 Q2	$2M	Hold	205,190	–	–	﹤0.01%	3709
2022 Q1	$2.02M	Sell	205,190 -485,768	-70%	-$4.8M	﹤0.01%	3871
2021 Q4	$6.85M	Sell	690,958 -2,542	-0.4%	-$25.2K	﹤0.01%	2569
2021 Q3	$6.89M	Sell	693,500 -14,132	-2%	-$140K	﹤0.01%	2514
2021 Q2	$7.07M	Sell	707,632 -162,368	-19%	-$1.62M	﹤0.01%	2313
2021 Q1	$8.76M	Buy	+870,000	New	+$8.69M	0.01%	1929

Millennium Management's EBACU Position: Q1 2023 in Review

Millennium Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q1 2023, closing a stake of 200,000 shares — an estimated $2.01M sold.

Millennium Management first reported a position in EBACU in Q1 2021 and held it in 8 quarters. The position peaked at $8.76M in Q1 2021. 0 funds tracked by Wall St. Rank hold EBACU as of Q1 2023.

Millennium Management reported no remaining European Biotech Acquisition Corp. Units position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 200,000 European Biotech Acquisition Corp. Units shares in Q1 2023, an estimated $2.01M.
Millennium Management first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 8 quarters.
Millennium Management's European Biotech Acquisition Corp. Units position peaked at $8.76M in Q1 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.